Lifesci Capital upgraded shares of Praxis Precision Medicines (NASDAQ:PRAX - Free Report) to a strong-buy rating in a research note issued to investors on Wednesday morning,Zacks.com reports. Lifesci Capital also issued estimates for Praxis Precision Medicines' Q3 2025 earnings at ($3.57) EPS, Q4 2025 earnings at ($3.26) EPS, FY2025 earnings at ($13.42) EPS, Q1 2026 earnings at ($3.41) EPS, Q2 2026 earnings at ($3.07) EPS, Q3 2026 earnings at ($3.40) EPS, Q4 2026 earnings at ($3.39) EPS and FY2026 earnings at ($13.26) EPS.
Several other equities research analysts have also recently weighed in on PRAX. Needham & Company LLC reaffirmed a "buy" rating and issued a $80.00 price target on shares of Praxis Precision Medicines in a research report on Thursday, June 12th. Oppenheimer upped their price target on shares of Praxis Precision Medicines from $97.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Chardan Capital reaffirmed a "buy" rating and issued a $80.00 price target on shares of Praxis Precision Medicines in a research report on Tuesday, July 29th. HC Wainwright reaffirmed a "buy" rating and issued a $115.00 price target (up previously from $105.00) on shares of Praxis Precision Medicines in a research report on Tuesday, August 5th. Finally, Jefferies Financial Group reaffirmed a "buy" rating on shares of Praxis Precision Medicines in a research report on Tuesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has given a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $85.88.
Get Our Latest Research Report on PRAX
Praxis Precision Medicines Price Performance
PRAX stock traded down $2.41 during mid-day trading on Wednesday, reaching $38.35. The company had a trading volume of 208,129 shares, compared to its average volume of 449,336. The company has a market capitalization of $807.16 million, a PE ratio of -3.12 and a beta of 2.61. The firm has a 50 day moving average of $49.43 and a 200 day moving average of $42.66. Praxis Precision Medicines has a 12 month low of $26.70 and a 12 month high of $91.83.
Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its earnings results on Monday, August 4th. The company reported ($3.31) EPS for the quarter, topping analysts' consensus estimates of ($3.40) by $0.09. Praxis Precision Medicines had a negative net margin of 2,137.48% and a negative return on equity of 60.07%. Analysts anticipate that Praxis Precision Medicines will post -10.22 EPS for the current year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC raised its holdings in shares of Praxis Precision Medicines by 88.3% in the second quarter. Nisa Investment Advisors LLC now owns 629 shares of the company's stock worth $26,000 after buying an additional 295 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Praxis Precision Medicines in the fourth quarter worth $30,000. CWM LLC raised its holdings in shares of Praxis Precision Medicines by 877.9% in the second quarter. CWM LLC now owns 753 shares of the company's stock worth $32,000 after buying an additional 676 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in shares of Praxis Precision Medicines by 24.3% in the second quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company's stock worth $77,000 after acquiring an additional 359 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Praxis Precision Medicines by 6,075.4% in the first quarter. GAMMA Investing LLC now owns 4,014 shares of the company's stock worth $152,000 after acquiring an additional 3,949 shares during the period. Hedge funds and other institutional investors own 67.84% of the company's stock.
About Praxis Precision Medicines
(
Get Free Report)
Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.
Further Reading
Before you consider Praxis Precision Medicines, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.
While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
